Announcements Trials
Browse Landscape

Status

No longer available 1Available 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 40Observational 4Expanded_access 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2

Interventions

nilotinib 5dabrafenib 4Nivolumab 4Afatinib 4trametinib 3regorafenib 3midostaurin 3elotuzumab 3TIC10 compound 3Sunitinib 3Prednisone 3Capecitabine 3Abiraterone Acetate 33-Iodobenzylguanidine 3venetoclax 2tucatinib 2tempol 2tazemetostat 2talquetamab 2talimogene laherparepvec 2ruxolitinib 2pomalidomide 2olaparib 2niraparib 2leronlimab 2lenvatinib 2ibrutinib 2gilteritinib 2ceritinib 2brexucabtagene autoleucel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Expanded_access × Alpelisib × Clear all
NCT04085653 2026-04-14

Managed Access Programs for BYL719, Alpelisib

Novartis

Available
Breast

Breast Neoplasms

NCT03706573 2021-07-19

Managed Access Program to Provide Alpelisib for Patients With HR+ Advanced or Metastatic Breast Cancer

Novartis

No longer available
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡